Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LCTG-003
- Development stage
- Preclinical
- Lead developer
- Lactiga
01
Overview
**LCTG-003** is a preclinical drug candidate developed by Lactiga, Inc., targeting immune system diseases and infectious diseases. Specific details on its mechanism of action, indications, or clinical data are limited in available sources, with its global highest R&D status reported as preclinical.[3][16]
Beyond the preview
Go deeper on LCTG-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LCTG-003.